Glycyrrhizin(Glycyrrhizic Acid)

Molecular Weight (MW)	822.93
Formula	C42H62O16
CAS No.	1405-86-3
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 117 mg/mL (142.25 mM)
Water: <1 mg/mL
Ethanol: 165 mg/mL (201.0 mM)
Solubility (In vivo)	Chemical Name: (2S,3S,4S,5R,6R)-6-(((2S,3R,4S,5S,6S)-6-carboxy-2-(((3R,4aR,6aR,6bS,8aS,11R,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)-4,5-dihydroxytetrahydro-2H-pyran-3-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid InChi Key: LPLVUJXQOOQHMX-ACOLGLFUSA-N InChi Code: InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22+,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39+,40-,41+,42+/m0/s1 SMILES Code: O[C@@H]([C@@H]([C@@H](C(O)=O)O1)O)[C@@H](O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](C(O)=O)O2)O)O)O)[C@H]1O[C@@H](C(C)([C@](CC[C@@]([C@@]3(CC[C@]4(CC[C@](C[C@]4(C3=C5)[H])(C(O)=O)C)C)C)6C)7[H])C)CC[C@]7(C)[C@@]6([H])C5=O
Synonyms	Glizigen; Liquorice; Glycyrrhizin;

Molecular Weight (MW)

822.93

Formula

C42H62O16

CAS No.

1405-86-3

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 117 mg/mL (142.25 mM)

Water: <1 mg/mL

Ethanol: 165 mg/mL (201.0 mM)

Solubility (In vivo)

Chemical Name: (2S,3S,4S,5R,6R)-6-(((2S,3R,4S,5S,6S)-6-carboxy-2-(((3R,4aR,6aR,6bS,8aS,11R,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)-4,5-dihydroxytetrahydro-2H-pyran-3-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid

InChi Key: LPLVUJXQOOQHMX-ACOLGLFUSA-N

InChi Code: InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22+,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39+,40-,41+,42+/m0/s1

SMILES Code: O[C@@H]([C@@H]([C@@H](C(O)=O)O1)O)[C@@H](O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](C(O)=O)O2)O)O)O)[C@H]1O[C@@H](C(C)([C@](CC[C@@]([C@@]3(CC[C@]4(CC[C@](C[C@]4(C3=C5)[H])(C(O)=O)C)C)C)6C)7[H])C)CC[C@]7(C)[C@@]6([H])C5=O

Synonyms

Glizigen; Liquorice; Glycyrrhizin;

In Vitro	In vitro activity: Glycyrrhizic acid shows a series of anti-cancer-related pharmacological activities, such as broad-spectrum anti-cancer ability, resistance to the tissue toxicity caused by chemotherapy and radiation, drug absorption enhancing effects and anti-multidrug resistance (MDR) mechanisms, as a carrier material in drug delivery systems[1]. In intestinal NCI-H716 cells that secretes GLP-1, Glycyrrhizic acid promotes GLP-1 secretion with a marked elevation of calcium levels. Glycyrrhizic acid can enhance GLP-1 secretion through TGR5 activation
In Vivo	Male Wistar rats were given 30, 60 or 120 mg/kg of GA twice a day for 2 weeks. Plasma corticosterone was decreased in those given the 120 mg dose, while urinary corticosterone excretion was increased in those given the 30 and 60 mg doses but decreased in those given 120 mg GA. NAD(+)-dependent dehydrogenase activity in kidney microsomal fraction was decreased in animals receiving doses of 60 and 120 mg GA. The 11-HSD2 protein and mRNA levels were decreased in those given 120 mg GA. In contrast, in vitro studies using mouse kidney M1 cells revealed that 24h treatment with glycyrrhetinic acid did not affect the 11-HSD2 mRNA expression levels. Thus, in addition to its role as a competitive inhibitor of 11-HSD2, the chronic high dose of GA suppresses mRNA and protein expression of 11-HSD2 possibly via indirect mechanisms. These effects may explain the prolonged symptoms after cessation of GA administration in some pseudoaldosteronism patients.
Animal model	Male Wistar rats
Formulation & Dosage	30, 60 or 120 mg/kg
References	J Steroid Biochem Mol Biol. 2002 Apr;80(4-5):441-7.

In Vitro

In vitro activity: Glycyrrhizic acid shows a series of anti-cancer-related pharmacological activities, such as broad-spectrum anti-cancer ability, resistance to the tissue toxicity caused by chemotherapy and radiation, drug absorption enhancing effects and anti-multidrug resistance (MDR) mechanisms, as a carrier material in drug delivery systems[1]. In intestinal NCI-H716 cells that secretes GLP-1, Glycyrrhizic acid promotes GLP-1 secretion with a marked elevation of calcium levels. Glycyrrhizic acid can enhance GLP-1 secretion through TGR5 activation

In Vivo

Male Wistar rats were given 30, 60 or 120 mg/kg of GA twice a day for 2 weeks. Plasma corticosterone was decreased in those given the 120 mg dose, while urinary corticosterone excretion was increased in those given the 30 and 60 mg doses but decreased in those given 120 mg GA. NAD(+)-dependent dehydrogenase activity in kidney microsomal fraction was decreased in animals receiving doses of 60 and 120 mg GA. The 11-HSD2 protein and mRNA levels were decreased in those given 120 mg GA. In contrast, in vitro studies using mouse kidney M1 cells revealed that 24h treatment with glycyrrhetinic acid did not affect the 11-HSD2 mRNA expression levels. Thus, in addition to its role as a competitive inhibitor of 11-HSD2, the chronic high dose of GA suppresses mRNA and protein expression of 11-HSD2 possibly via indirect mechanisms. These effects may explain the prolonged symptoms after cessation of GA administration in some pseudoaldosteronism patients.

Animal model

Male Wistar rats

Formulation & Dosage

30, 60 or 120 mg/kg

References

J Steroid Biochem Mol Biol. 2002 Apr;80(4-5):441-7.

CAS NO:	1405-86-3
规格:	≥98%

包装	价格(元)
50mg	电议
100mg	电议
250mg	电议
500mg	电议
1g	电议
2g	电议